Alder BioPharmaceuticals Inc. (Nasdaq: ALDR) reported upbeat results from a Phase 3 clinical trial of eptinezumab but the stock price plunged $5.23 to close at $13.48.
Alder BioPharmaceuticals plunges despite upbeat results
June 27, 2017 at 17:21 PM EDT
